chaga extract

Exenatide Acetate API Bulk Supply

Custom Peptide Synthesis • High-Purity GLP-1 Receptor Agonist

⚠Declaration:

This product is intended for industrial use and scientific research only. Not for human clinical medication, food or cosmetic application.

GMP STANDARD PHARMACEUTICAL PEPTIDE SUPPLIER

Exenatide Acetate Salt

CAS No.: 141732-76-5

PURITY (HPLC)

≥ 98.0%

MOLECULAR FORMULA

C184H282N50O60S · xCH3COOH

MOLECULAR WEIGHT

4304.65 Da (Acetate Salt)

PEPTIDE CONTENT / ACETATE

Custom / Controlled

💡 Quick Connection Notice: If your email link doesn't open, please directly send inquiries to: betty@pharma-sunrise.com

Request Bulk Quote

Request Peptide COA

Scientific Overview & Supply Chain Reliability

We specialize in supplying high-purity Exenatide Acetate active pharmaceutical ingredient (API) powder via advanced solid-phase peptide synthesis (SPPS) platforms. Meticulously monitored under standardized cGMP pharmaceutical quality control procedures, each manufactured batch undergoes complete structural verification and rigorous HPLC testing to ensure a stable purity level of 98% and above.

We recognize the critical importance of supply chain flexibility and rigorous batch reproducibility in innovative drug development. Consequently, we offer comprehensive packaging architecture across all lifecycle stages – from milligram-scale process exploration and pre-clinical assay evaluations to large-scale bulk kilogram commercial production, securely accelerating your targeted metabolic and diabetes therapeutics projects.

Pharmacological Action & Mechanism Profile

Mechanism Of Action (MoA)

Exenatide functions as a potent Glucagon-like Peptide-1 (GLP-1) receptor agonist. It targets metabolic pathways by mimicking the endogenous incretin hormone GLP-1, binding specifically to and activating the GLP-1 receptors on targeted cell membranes. This process triggers canonical intracellular signaling cascade pathways, including cyclic adenosine monophosphate (cAMP) accumulation. Crucially, compared to native GLP-1, exenatide exhibits significant structural resistance to enzymatic degradation by dipeptidyl ppetidase-4 (DPP-4), enabling an extended half-life in vivo and sustainable long-term blood glucose modulation.

Core Pharmacological Axes

• Glucose-dependent Insulin Modulation: Stimulates insulin release from pancreatic beta cells exclusively under elevated blood glucose conditions, substantially minimizing hypoglycemia profiles.

• Glucagon Suppression: Restrains the hyper-secretion of glucagon from pancreatic alpha cells, lowering overall hepatic glucose output.

• Delayed Gastric Emptying: Prolongs gastric food retention times, moderating intestinal nutrient absorption rates to blunt postprandial glucose spikes and elevate satiety lines.

• Appetite Regulation: Acts target-specifically on cerebral feeding centers to aid in appetite and food intake reduction models.

API Formulation Objectives & Clinical Reference Documentation

When successfully processed into finished pharmaceutical delivery systems, this active ingredient yields highly reproducible clinical references:

✔ Effective Glycemic Reduction: Potently mitigates both fasting and postprandial blood glucose markers in type 2 diabetes therapeutic assays.

✔ Sustainable HbA1c Control: Provides a stable, long-term lowering and maintenance of glycated hemoglobin (HbA1c) baselines.

✔ Beneficial Weight Management: Assists downstream weight maintenance models via biological satiety enhancement and delayed nutrient transit.

✔ Islet Cell Protection: Demonstrates a clear protective index on beta-cells by systematically alleviating glucotoxicity and lipotoxicity parameters.